In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Power Of Pradaxa: Physicians Weigh In

Executive Summary

With the worldwide market for novel oral anti-coagulants Pradaxa, Xarelto, and apixiban pegged at as much as $10 billion, how these drugs fare with physicians - and, importantly, payors - provides a case study for future big drug launches in an era where health care costs are a key consideration.
Advertisement

Related Content

Are Manufacturers Getting Better At Providing Data Payers Want? RegenceRX Weighs In
With Pradaxa On The Rise, Medco Gathers Evidence On Warfarin Diagnostic Testing
With Pradaxa On The Rise, Medco Gathers Evidence On Warfarin Diagnostic Testing
ROCKET AF Yields Positive Results For Xarelto, But A Few Chinks In The Armor
Oral Anticoagulants Market Snapshot: Big Bucks, But Payers Are On Guard

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003435

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel